title: Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur.
abstract: BACKGROUND
  Bacille Calmette-Guerin (BCG) is currently the only available vaccine against tuberculosis (TB) and comprises a heterogeneous family of sub-strains with genotypic and phenotypic differences. The World Health Organization (WHO) affirms that the characterization of BCG sub-strains, both on genomic and proteomic levels, is crucial for a better comprehension of the vaccine. In addition, these studies can contribute in the development of a more efficient vaccine against TB. Here, we combine two-dimensional electrophoresis (2DE) and mass spectrometry to analyse the proteomic profile of culture filtrate proteins (CFPs) from M. bovis BCG Moreau, the Brazilian vaccine strain, comparing it to that of BCG Pasteur. CFPs are considered of great importance given their dominant immunogenicity and role in pathogenesis, being available for interaction with host cells since early infection.
  
  
  RESULTS
  The 2DE proteomic map of M. bovis BCG Moreau CFPs in the pH range 3-8 allowed the identification of 158 spots corresponding to 101 different proteins, identified by MS/MS. Comparison to BCG Pasteur highlights the great similarity between these BCG strains. However, quantitative analysis shows a higher expression of immunogenic proteins such as Rv1860 (BCG1896, Apa), Rv1926c (BCG1965c, Mpb63) and Rv1886c (BCG1923c, Ag85B) in BCG Moreau when compared to BCG Pasteur, while some heat shock proteins, such as Rv0440 (BCG0479, GroEL2) and Rv0350 (BCG0389, DnaK), show the opposite pattern.
  
  
  CONCLUSIONS
  Here we report the detailed 2DE profile of CFPs from M. bovis BCG Moreau and its comparison to BCG Pasteur, identifying differences that may provide relevant information on vaccine efficacy. These findings contribute to the detailed characterization of the Brazilian vaccine strain against TB, revealing aspects that may lead to a better understanding of the factors leading to BCG's variable protective efficacy against TB.
authors.affiliation: Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, FIOCRUZ, Avenida Brasil, 4365, Manguinhos, CEP 21040 -900 Rio de Janeiro, RJ, Brazil.
authors.forename: Marcia
authors.initials: M
authors.lastname: Berrêdo-Pinho
authors.forename: Dario E
authors.initials: DE
authors.lastname: Kalume
authors.forename: Paloma R
authors.initials: PR
authors.lastname: Correa
authors.forename: Leonardo H F
authors.initials: LH
authors.lastname: Gomes
authors.forename: Melissa P
authors.initials: MP
authors.lastname: Pereira
authors.forename: Renata F
authors.initials: RF
authors.lastname: da Silva
authors.forename: Luiz R R
authors.initials: LR
authors.lastname: Castello-Branco
authors.forename: Wim M
authors.initials: WM
authors.lastname: Degrave
authors.forename: Leila
authors.initials: L
authors.lastname: Mendonça-Lima
mesh_terms: D001500:BCG Vaccine / Q000378:metabolism*; D001426:Bacterial Proteins / Q000032:analysis*; D001938:Brazil; D003470:Culture Media / Q000737:chemistry*; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D013058:Mass Spectrometry; D009163:Mycobacterium bovis / Q000254:growth & development* / Q000378:metabolism*; D020543:Proteome / Q000032:analysis*
chemical_list: D001500:BCG Vaccine; D001426:Bacterial Proteins; D003470:Culture Media; D020543:Proteome